Zdrowie i gospodarka · 19/08/1999
FDA Proposes Regulations for Tracking and Notification of Blood-Derived Products
The FDA plans to require tracking and notification of certain blood-derived products, including plasma derivatives, from licensed manufacturers to patients, in the event of a potential increased risk of disease transmission.